French biotech - Exhibitors, exhibiting companies

	ALCIMED BIOTECHNOLOGIES

57 boulevard de Montmorency
75016 PARIS - FRANCE

Phone : +33 144 304 430
Fax : +33 144 304 431
Web Site : www.alcimed.com

ALCIMED is a European consulting and decision aid company specialized in the fields of Life Sciences (Pharmaceutical, Diagnostic, Biomedical, Biotechnology) and Chemistry. ALCIMED exists to help decision-makers in their positioning and development choices, and to help them to grasp opportunities (new products / markets, cutting-edge technologies,…) and adapt to threats (changes in regulation, arrival of new competitors,…). Our main areas of expertise are R&D, Marketing and Corporate strategies at the interface between sciences and business. From specializing initially in biotechnology, ALCIMED has gradually extended the scope of its decision aid activity into the Life Sciences and their many fields of application, health, food, cosmetics, environment and chemicals. ALCIMED relies on a team remarkable for its culture of wide-ranging general expertise and its high standards of education and training: 100 high level biologists and chemists having a dual scientific / economic background. We handle varied assignments at the interface between Science and Business, such as market studies, strategic analysis, business plans, business development and product marketing strategy.

BIOVALLEY

Parc d'Innovation - 9 Bd Gonthier d'Andernach
67400 Illkirch - FRANCE

Phone : +33 390 403 000
Fax : +33 390 403 001
Web Site : www.biovalley.com

Alsace BioValley is one of the top three BioClusters in Europe, assembling both world class public research and training with industry leaders in Pharma and Biotech. Our cluster organization offers a wide range of services and financial incentives to help foreign companies either develop partnerships with BioValley players, or explore the advantages of creating activities in Alsace to cover parts of European markets.

ATLANTIC BIOTHERAPIES

C/O Atlanpole - Château de la Chantrerie
BP 90702
44307 NANTES Cedex 03 - FRANCE

Phone : +33 240 252 720
Fax : +33 240 251 088
Web Site : www.atlantic-biotherapies.com

From drug discovery to clinical evaluation, the “Atlantic
Biotherapies” French competitiveness cluster brings together all the stakeholders in the development of biological drugs. With 32 companies and 28 academic research units, this cluster is responding to new challenges in human healthcare: to discover and produce the drugs of tomorrow.


	AVOGADRO

Parc de Génibrat
31470 Fontenilles - FRANCE

Phone : +33 562 147 314
Fax : +33 562 147 310
Web Site : www.avogadro-lab.com

AVOGADRO is an independent CRO with 95 scientists (location Cambridge, MA and Toulouse, France - full GLP/GMP compliance) specialising in Pharmaceutical Analysis (method development and validation, stability studies), Quality Control, Bioanalysis (LC/MS/MS assays), ADME (including metabolite profiling and identification), Pharmacokinetics (Bioavailability, Bioequivalence), Residues, Target Animal Safety, Environmental Impact Assessment and Biochemistry (lipoprotein profiles) PHARMACEUTICAL ANALYSIS: - Development, validation and transfer of analytical methods, - Stability testing of active substances, medicinal products & clinical batches (ICH/VICH). QUALITY CONTROL: - Physico-chemical characterisation on various products, - Limit tests (residual solvents, heavy metals), - Sourcing of active ingredients, - Analytical batch release (clinical batches & marketed products). BIOANALYTICAL CHEMISTRY & DRUG METABOLISM: - Development & validation of analytical methods, - Pharmacokinetic studies, bioavailability, bioequivalence, - Early PK studies, - Metabolism studies (ADME), - Residue depletion studies, - Ecotoxicological studies. IN-LIFE PHASE STUDIES: - Laboratory species, - Food-producing species, - Local & general tolerance studies in target species. BIOCHEMISTRY: - Lipoprotein profiles. QUALITY: - Full GLP compliance, - Full GMP compliance (QC analysis, stability studies), - ISO 14001 certification (Environment Management System).


	BIOALLIANCE PHARMA

59, boulevard du Général Martial Valin
75015 Paris - FRANCE

Phone : +33 145 587 600
Fax : +33 145 580 881
Web Site : www.BioAlliancePharma.com

CORPORATE PROFILE BioAlliance Pharma is a privately held late-stage biopharmaceutical company focused on drug resistance through development and commercialization of innovative therapeutics that target cancer, HIV, severe infections and supportive care. The targeted sales for company products are more than €1 billion ($1.3 billion), of which €500 million ($660 million) represent near term sales generated by the Company’s Phase III-driven lead product pipeline, with direct or indirect revenues resulting from product launches beginning in 2006/2007, together with a planned exit for investors through an IPO or the M&A market in the same time frame. TECHNOLOGY OVERVIEW / AREA OF EXPERTISE To attack the challenge of drug resistance, BioAlliance has multiple product opportunities in two broad proprietary drug delivery systems represented by the Lauriad® adhesive technology and the Transdrug® nanoparticle technology. Coupled with its New Chemical Entities (NCE) program, which focuses on new drug development in oncology and HIV, the Company is able to address worldwide markets in the EU, U.S, and Asia.


	BIOCITECH

102 Route de Noisy
93230 ROMAINVILLE - FRANCE

Phone : +33 149 913 102
Fax : +33 149 913 103
Web Site : www.biocitech.com

Situated at the gateway to Paris, just twenty minutes from the Gare du Nord international train station and Charles de Gaulle airport, BIOCITECH® comprises of approximately 100,000 sq. ft of state-of-the-art facilities comfortably spread over 20 acres. With its cutting-edge laboratories, the Park offers the highest standards in security, technology, confidentiality and environmental protection – available around-the-clock. Specialized in life sciences, BIOCITECH®’s services are mainly targeted at biotechnology companies, CROs, and foreign companies looking for the best possible conditions for their European expansion. BIOCITECH® tenants benefit from a wide array of high quality services including building management, conference rooms, a 250-seat auditorium, first class accommodation and office-support facilities. The Park’s large, communal spaces and shared dining facilities create a friendly, collegial atmosphere, a perfect environment for nurturing cross-organizational collaboration. The close proximity of numerous companies dedicated to the life sciences, hospitals, universities and academic researchers, is a natural breeding ground for new ideas, fostering innovation and development. BIOCITECH® is strongly involved in the development of Paris Region Biocluster.


	BIOCORTECH

Pasteur Biotop, 28 rue du Dr Roux
75015 Paris - FRANCE

Phone : +33 145 688 122
Fax : +33 147 832 776
Web Site : www.biocortech.com

Biocortech develops new pharmaceutical compounds active on the Central Nervous System to treat neuropsychiatric disorders. The company is focused on depression, bipolar disorders and cognitive deficits. Biocortech strategy is to develop new pharmaceuticals able to i) restore deficient pathways in the adult brain or ii) deficient receptors via the modulation of mRNA editing mechanisms. The already selected drug candidates overcome key limitations of anti-depressant.


	BIO-MODELING SYSTEMS

26 RUE SAINT LAMBERT
75015 PARIS - FRANCE

Phone : +33 683 061 272

Our company elaborates immediately exploitable comprehensive predictive biological models directly leading to significant improvements in the success-rate of drug development. We have repeatedly demonstrated, in a wide variety of therapeutic domains (from cancers to neurological and immunological disorders), our unique ability to successfully carry-out this highly specialised task and to achieve and deliver the expected end results: -We find and validate new therapeutic/pathological/side effects mechanisms; -We find and validate the mechanisms of action for novel small molecules, -We find and validate new therapies from client's existing drug and target portfolios. BUSINESS PROPOSAL BIO-MODELING SYSTEMS is currently the only biotech company specialised in Predictive Integrative Biology that has the proven ability to deliver validated solutions, immediately applicable throughout the drug development process, to support and secure industrial sales and profits. We sell, in the context of collaborative agreements, 1.Physiologically validated mechanisms of drugs/targets therapeutic actions, including toxicological aspects and exclusion criteria, to accelerate and secure the drug discovery & development processes (including clinical trials); 2.Physiologically validated mechanisms of novel therapeutic approaches for poorly served pathologies; and 3.New therapeutic uses of existing drugs, diversifying their domains of application.


	BIONEST PARTNERS

13 rue Vivienne
75002 Paris - FRANCE

Phone : +33 158 051 400
Fax : +33 158 051 409
Web Site : www.bionest.com

Bionest Partners provides advisory and management services to help biotechnology, specialty pharmaceutical and medical device companies and their shareholders maximize the value of their assets. The company offers a hands-on approach, and its areas of expertise include management consulting (strategy, organization, marketing, due diligence, surrogate management), corporate finance (private placement, IPO support, out-licensing, in-licensing, mergers and acquisitions), entry into Europe (assessment, strategy, go-it-alone/partnering, management support). Bionest has a strong and growing team of consultants as well as a network of associate members which it deploys to address specific client assignments.


	BIOTECHNIMES

Parc georges Besse Site EERIE 69 avenue Georges Besse
30035 NIMES Cedex 1 - FRANCE

Phone : +33 466 384 089
Fax : +33 466 047 324
Web Site : www.biotechnimes.org

BiotechNîmes is an economic development agency based in the south of France whose role is to assist in the implantation and development of companies; especially in life sciences. BiotechNîmes provides operational customised solutions for biotech companies which have chosen to set up in Nîmes Nîmes is situated in the heart of Southern Europe. The important communication networks, the number of life science organisations situated within a few kilometres, the highly qualified workforce... give good perspectives of development to biotech companies. Businness plan - Incubators.


	BIOTRIAL

CRO Contract Research Organisation 7-9, rue Jean-Louis Bertand
35000 Rennes - FRANCE

Phone : +33 299 599 191
Fax : +33 299 599 199
Web Site : www.biotrial.com

• Phase I to IV, Biostats & Data Management, Medical Writing • Preclinical pharmacology • Phase I clinics in Paris (24 and 34 beds) and Rennes (92 beds) • FIM and PK/PD studies • Special collaboration with important cancer centres • Special populations: Alzheimer disease, Asthma, Cancer, Coronary diseases, Diabetes type II, Dyslipideamia, Elderly, Hepatically impaired, HIV, Hepatitis C, Hypertension, Irritable Bowel Syndrome, Multiple Sclerosis, Parkinson, Postmenopausal women... Therapeutic areas : Allergy & Immunology Cardiovascular CNS Dermatology Endocrinology/Metabolism Gastro-enterology Hematology Respiratory diseases Infectious diseases Oncology.


	BRETAGNE INTERNATIONAL

Collective Missions Department 16 C RUE JOUANET
35708 RENNES CEDEX 7 - FRANCE

Phone : +33 299 250 404
Fax : +33 299 250 400
Web Site : www.bretagne-international.com

BRETAGNE INTERNATIONAL is a 20 years old association created and supported by the Regional governement of Bretagne and companies located in Bretagne (Werstern France). Bretagne International is fully dedicated to the international development of local companies: export, partnership, sourcing, ... Bretagne International can assist your company in finding partners in France in order to initiate operations in Europe.


	BT PHARMA

Prologue-Biotech Rue Pierre et Marie Curie BP 28262
31682 Labège - FRANCE

Phone : +33 561 287 060
Fax : +33 561 287 069
Web Site : www.btpharma.com

BT PHARMA contributes to human health through the commercial development of immuno-thérapeutics and vaccines from proof of concept to clinical trials phase I & II. BT PHARMA is expert in pré clinical and clinical development of immuno-thérapeutics based on a proteineous vector that functions as a "nano" seringe that targets antigens into dendritic cells in vivo and induces a dual cellular immune response mediated by CD8+ (CTL) and CD4+ (Th1) T cells.


	CELLECTIS

102 Route de Noisy
93235 Romainville Cedex - FRANCE

Phone : +33 141 839 900
Fax : +33 141 839 903
Web Site : www.cellectis.com

CELLECTIS is the world leader in applying the technology of Meganuclease Recombination Systems to in vivo genome engineering and genome surgery. The company is focused on the research and development of custom-Meganuclease Recombination Systems for in vivo DNA interventions and also provides new tools for rational genome engineering and targeted recombination in living cells. CELLECTIS develops recombination systems based on a novel class of genetic scissors: the Meganucleases. The technological breakthrough is the Meganuclease Recombination Systems (MRS) based on the Homologous Recombination and the Meganucleases. Cellectis' technology allow to perform precise modifications on chromosomes such as deletions, insertions or substitutions of genomic sequences. We design the meganuclease to target sequences of interest in the genome in vivo or ex vivo. CELLECTIS products are patented proprietary technologies. Applications of Meganuclease Recombination Systems (MRS)cover human genome therapy (somatic, stem cells and anti-viral), animal models, protein production and bioprocessed molecules or genetic improvement of plant or animal species.

CIT SAFETY & HEALTH RESEARCH LABORATORIES

BP 563
27005 Evreux - FRANCE

Phone : +33 232 292 626
Fax : +33 232 678 705
Web Site : www.citox.com

Located near Paris, CIT is an independent contract research organization working actively with international pharmaceutical and biotechnology companies. With 340 full time employees, CIT offers an extensive range of services in all main fields of toxicology such as general toxicology, reprotoxicology, genetic toxicology, carcinogenicity, pharmacokinetics, toxicokinetics, histopathology, safety pharmacology and special pharmacology like bone studies and lipid metabolism. - primate studies - bone toxicology and pharmacology - carcinogenicity studies in transgenic mice - reproductive hormone studies.


	CLEAN CELLS

Parc d'Activités Vendée Sud-Loire 1
0 Boufféré - FRANCE

Phone : +33 251 092 757
Fax : +33 251 092 758
Web Site : www.clean-cells.fr

Clean Cells provides GLP in vitro / in vivo services supporting the biotechnological development from R&D stage to clinical trials (recombinant proteins, vaccines, cell and gene therapy products) in compliance with the regulatory requirements (FDA, Eu. Ph., ICH...). - Biosafety testing (mycoplasma, sterility, viruses, endotoxins, residual DNA...), - Cell characterization studies (isoenzymes, DNA finger printing, karyology...), - Cell production (Master Cell Bank / Working Cell Bank) and cell storage solutions. - Process validation : viral clearance, media fertility testing. - Customized cell R&D bioassays and studies (e.g. clone selection, primary cells immortalization, viral vector productions...).

CRID PHARMA - CLIPA

17 Parc des Vautes
34983 Saint Gély du Fesc - FRANCE

Phone : +33 499 583 860
Fax : +33 499 583 861
Web Site : www.cridpharma-clipa.com

CRID Pharma – CLIPA proposes comprehensive, full service and integrated services to prepare Clinical Trial Materials, for phase I-IV studies, for human and veterinary drugs. CRID Pharma -CLIPA is not affiliated to any pharmaceutical or biotech company. GMP Compliant. - Importation, control and release of clinical supplies. - Manufacturing and packaging of clinical supplies - Storage and distribution in Europe - Pharmaceutical development : stability studies under ICH conditions, formulation and method validation, pharmaceutical writing (IMPD...).

CRITT SANTE BRETAGNE

Innovation & Technology Transfer Centre in Brittany 2 avenue du Président Leon Bernard CS 34317
35043 Rennes Cedex - France - FRANCE

Phone : +33 223 234 581
Fax : 33 223 234 586
Web Site : http://www.critt-sante.fr

The CRITT works for R&D research units and companies involved in research and development of health-related in Brittany, Western-France (70 public research units, 150 small size companies), to support and develop partnerships, to provide technological assistance, to assist project leaders, to promote and support development of BME.


	CYTOMICS SYSTEMS

1 avenue de la Terrasse Bat 5
91190 Gif-sur-Yvette - FRANCE

Phone : +33 169 824 266
Fax : +33 169 824 238

CYTOMICS SYSTEMS is a biopharmaceutical company pioneering the discovery and development of drugs that control the degradation of proteins, to treat major human diseases. The Company was founded by Dominique Thomas, PhD, Director of Research at the CNRS Center for Molecular Genetics. The Company has developed an innovative high-throughput screening technology, UbiScreen®, for the discovery of new therapeutic molecules controlling the degradation of target proteins. CYTOMICS SYSTEMS has used this technology to target fungal infections with compounds at the preclinical stage. Another drug development program in the field of oncology has led to the selection of very promising molecules.


	DBV TECHNOLOGIES

88, avenue Leclerc
92100 Boulogne Billancourt - FRANCE

Phone : +33 155 389 270
Fax : +33 141 312 882
Web Site : www.dbv-technologies.com

DBV has created E-patch® technology for cutaneous administration of active ingredients and is using it in the development of product ranges for diagnosis and treatment. DBV Technologies developed a way of delivery for larger and more fragile drug molecules to pass into the skin, opening the possibilities for controlled, pain-free delivery of virtually any drug or vaccine. The E-patch technology allows to a cost-effective and easy to use skin patch, holding the dry drug by electrostatic forces by passing cold chain constraints. The occlusion created on the skin facilitates the flow of non-denatured proteins, peptides, and other molecules into the body without the use of needles.


	EDELRIS

115, Avenue Lacassagne
69003 Lyon - FRANCE

Phone : +33 437 561 901
Fax : +33 472 338 459

Edelris provides innovative and non-exclusive libraries of natural product-mimetic compounds that dramatically increase the potential to find viable hits. These non-aromatic, easily accessible and conformationally adaptable molecules are a far cry from the typical flat heterocyclic templates; They feature medchem-optimized five to nine-membered rings scaffolds bearing side chains that modulate overall physiochemical properties. The presence of biologically pertinent natural product functionalities, make these unique three-dimensional scaffolds excellent medchem starting points for accelerated hit discovery and smoother optimization. Medicinal Chemistry Services: Edelris provides a lead optimization and fine tuning service based on the company’s extensive knowledge in drug discovery. The management team, which has more than 60 years’ combined medchem experience gained with companies such as Merck Santé, Rhône-Poulenc, Aventis and Bayer, has led research efforts resulting in the invention of several products reaching the market or preclinical and clinical stages, in fields such as antifungals, diabetes and the treatment of cardiovascular disease. Based on this track record and with a team of flexible and experienced chemists, Edelris is well equipped for hit-finding activities and fine tuning early- or late-stage drug candidates, and works in close collaboration with customers ranging from biotech start-ups to major pharma. The company operates state-of-the-art laboratory facilities in Lyon, France, equipped with high-field NMR, several analytical and preparative LC/MS systems and a dedicated anthropomorphic sample handling robot, and Gilson and Genevac sample processing systems.

ERYTECH
PHARMA

60 avenue Rockefeller
69008 LYON - FRANCE

Phone : +33 487 444 38
Fax : +33 487 556 29
Web Site : www.erytech.com

ERYtech Pharma is a biotech company specialized in the encapsulation of therapeutic molecules or enzymes into red blood cells. By relying on red blood cells properties, ERYtech Pharma achieves a major breakthrough in the fields of cancer and enzyme therapies and significantly increases the therapeutic index of the encapsulated molecules or enzymes. The first product to originate from ERYtech Pharma's in-house R&D is GRASPA, encapsulated asparaginase. GRASPA is currently in Phase II for the treatment of acute lymphoblastic leukemia in adults and children. GRASPA relies on an innovative concept, the Cleav'ERY System®, enzyme cleaving inside the erythrocyte without delivery. This unique application offers a new solution for the use of therapeutic enzymes by increasing their half life and reducing their toxicity. ERYtech Pharma has also developed the Oxygen'ERY System® which is based on one of the main functions of red blood cells, bringing oxygen to tissues, and which can be applied to the fields of tissue and tumour oxygenation. GR-ARA1, encapsulated hemoglobin allosteric effector, is aimed at chronic and genetic diseases characterized by hypoxia and anemia such as sickle cell anemia and thalassemia. It is also aimed at radioresistant hypoxic tumours such as glioblastomas and ENT tumours. ERYtech Pharma's third product, GR-DD1, is an encapsulated cytostatic molecule for the treatment of hepatic metastases in colorectal cancer. This product is developed using the Deliv'ERY System®, a natural and specific targeting system. ERYtech Pharma has developed an innovative technological process which makes its possible to produce, on an industrial scale, a constant quality of processed erythrocytes whatever their initial characteristics are and whether they come from patients or not. Protected by an international patent, this technological process is characterized by its safety and its reproducibility. An ERYcaps machine has been operationnal since 2004 and is currently used for the production of the company's clinical batches.


	EURASANTÉ

Parc Eurasanté - 310 Avenue Eugène Avinée
59120 LOOS les LILLE - FRANCE

Phone : +33 328 559 060
Fax : +33 328 559 061
Web Site : www.eurasante.com

Eurasanté, a regional agency dedicated to the development of Biotechnology and Healthcare related activities, assists French and foreign companies wishing to set up in Lille/Nord-Pas de Calais Region. Eurasanté ensures the promotion of the Eurasanté Park, a site fully devoted to the biohealth sector. Covering nearly 750 acres, the Eurasanté Park is situated within the Lille University Hospital Complex and offers a truly unique environment specialized in biology and health. With 11,000 health professionals active in the Lille CHRU (Regional University Hospital Center), the Schools of Medicine and Pharmacy, the Oscar Lambret Center and many other institutions, the Eurasanté Park is the leading university hospital center in Europe.


	EUROBIO LILLE 2007

GL Events
Package Organisation Cité Internationale
10 quai Charles de Gaulle |
69463 Lyon - FRANCE

Phone : +33 478 176 176
Fax : +33 478 176 257
Web Site : www.eurobio-event.com/

EuroBiO 2007 will take place in Lille from the 26th to the 28th of September. EuroBiO is the unique European event gathering more than 5,000 key players in the bioscience and bio-industry sectors. The 4 pillars, conferences, a trade show, a business convention and a recruitment drive will bring together industry, research and finance partners.


	FAUST

BIOPARC BD Sebastien Brant
67400 Illkirch - FRANCE

Phone : +33 390 406 150
Fax : +33 390 406 155
Web Site : www.faustpharma.com

FaustPharmaceuticals is a clinical-stage product company focused on neurological and neuromuscular disorders. Our lead compound, FP0011, is a glutamate inhibitor in Phase II targeting Parkinson's disease and ALS. Our next lead, FP0023, is a utrophin inducer in preparation to enter Phase I for Duchenne Muscular Dystrophy. We additionally have pre-clinical programs against targets such as mGluR, and proprietary research engines for the discovery of small molecules acting on G-protein-coupled receptors (GPCRs), as well as for re-purposing drugs for neuroprotection. FaustPharmaceuticals has proprietary research platforms that both generate candidates for internal drug development and are availablel for collaboration with strategic partners to identify new drugs for the treatment of diseases of the central nervous system and others areas of high medical need. NeuroclidTM platform : early identification of ligand-receptor interactions through a proprietary and innovative FRET technology, for the discovery of GPCR allosteric modulator. NeuroprotecTM is a drug repositioning platform dedicated to identifying neuroprotective properties of marketedor clinical-stage drugs.


	FLUOFARMA

2 rue Robert Escarpit
33600 PESSAC - FRANCE

Phone : +33 540 003 060
Fax : +33 540 003 008

Fluofarma has developed a unique High-Content Screening (HCS) platform dedicated to drug discovery programs, through contracted service partnerships. Fluofarma has developed an innovative High Content Screening platform (HCS) with unique biosensors for target validation and drug discovery. Fluofarma’s biosensor-based HCS allows in situ quantitative analysis of molecular events by automated high throughput flow cytometry and confocal imaging. This proprietary technology can be applied in vitro to cell lines and in vivo via transgenic animals. Fluofarma is dedicated to cancer, excitotoxicity and CNS diseases.


	FORENAP PHARMA

27 rue du 4eme RSM 68250 Rouffach - FRANCE

Phone : +33 389 787 124
Fax : +33 389 785 124
Web Site : www.forenap.asso.fr

Forenap is an International Contract Research Organisation (CRO) specialised in early Drug Development and Research in Neurosciences. Since 1986, Forenap has been active in the clinical and pre-clinical development of new pharmaceutical compounds providing full range of in-services. Our structure and network enable us to carry out a “full service package” and offer consultancy services from Drug Discovery to Marketing Authorisation. Collaboration expected : ð Partenariat R&D : Pharmaceutical industries Cosmetological industries Agro & Food industries Hygiene and cleaning companies Societies for in vivo assays. ð Contract research : Pharmaceutical industries Cosmetological industries Agro & Food industries Hygiene and cleaning companies Societies for in vivo assays.


	FOVEA PHARMACEUTICALS

12 rue jean-Antoine de Baïf
75013 PARIS - FRANCE

Phone : +33 144 164 242
Fax : +33 144 164 240
Web Site : www.fovea-pharma.com

Created in 2005, Paris-based Fovea is an integrated drug discovery and development company focused on ocular diseases. With the scientific leadership and clinical expertise of Pr José-Alain Sahel and the team assembled at Fovea, the Company is uniquely positioned to capitalize on the growth of this market by developing drugs addressing unmet needs in the eye. Our strategic vision is to build Fovea into a major specialty pharmaceutical company in ophthalmology, based on both a strong discovery and development engine and an extensive knowledge and network in the field allowing for the identification of the most promising product opportunities.”


	GENEPEP S.A.

Cap Alpha Avenue de l'Europe Clapiers
34940 MONTPELLIER Cedex CEDEX 9 - FRANCE

Phone : +33 662 779 858
Fax : +33 467 548 654
Web Site : www.genepep.com

R&D: Genepep uses its proprietary bio-informatics platform to identify new natural peptides from the genomes of all the organisms sequenced, presenting a high chemical diversity, to predict natural modifications and finally synthesize them for R&D use. Focus on peptides with a high probability of lytic activity : anti-bacterial or anti cancerous activities of binding to orphan membrane receptors (Type RCPGo) Services: custom peptide synthesis, Analysis, optimization. Bioinformatique: discovery of new natural peptides from variuous genomes (human, plants, insects, microorganisms) Chemistry: Peptide and pseudopeptide synthesis, LC/MS analysis, SAR studies.


	GENFIT

Parc Eurasanté LILLE Métropole 885 avenue Eugène Avinée
59120 LOOS - FRANCE

Phone : +33 320 164 000
Fax : +33 320 164 001
Web Site : www.genfit.com

GENFIT, based in Lille (France) and Cambridge (MA), is an emerging bio-pharmaceutical company focused on the prevention and treatment of Cardiovascular Diseases and associated disorders, such as Dyslipidemia, Obesity and Diabetes. Our drug discovery and development expertise is based on cutting-edge technologies focused on our main pathologies of interest. They include functional genomics and proteomics, molecular biology, biochemistry, medicinal chemistry, screening, pharmacology and in vivo testing.


	GENOPOLE®

2, rue Gaston Cremieux CP 5723
91057 EVRY CEDEX - FRANCE

Phone : +33 160 878 318
Fax : +33 160 773 876
Web Site : www.genopole.fr

Genopole® is the leading French Science Park dedicated to life sciences. It is strategically positioned in the Paris Region Cluster to benefit from world-class hospitals, pharma and biotech companies and top-ranked international business schools. Genopole combines on a single site academic and private research laboratories, higher university education, biotechnology companies, and an incubator for start-ups. Genopole® is developing a large scale multidisciplinary research center dedicated to genomics, post-genomics and applications, involving 3 national scale research centers (Genoscope, National Genotyping Center, Genethon). Genopole® catalyzes the development of biotech companies (Business Incubation, Pre-seed Fund, Early stage Biotech Greenhouse) in the following fields: Biopharmaceuticals, Bioinformatics, Agri-Biotech & Environment, Chemistry ... ... FROM THE 1st DAY TO THE MARKET ACCEPTANCE Genopole® provides scientific facilities and services like an Animal Model Facility, an Atomic Force Microscope, an Imaging and Electron Microscopy Facility, a Transcriptome Platform, etc. Genopole® develops a network with institutional, scientific & industrial partners in Europe and in the world (USA, Canada, Japan, China, Israel, ...) Genopole® is involved in 3 European consortia: - BioLink: setting up of a "tool box" for best incubation practices - Natibs: allowing start-up Cies to have access to the R&D programs of the EC - CEBR: setting up of cooperation tools between bio-regions.


	GENOWAY

181 avenue Jean Jaurès
0 LYON - FRANCE

Phone : +33 437 654 100
Fax : +33 437 654 101
Web Site : www.genoway.com

genOway is dedicated to the development of tailor-made genetically modified rat and mouse models of the highest reliability. Based on innovative proprietary technologies and strategic alliances, genOway proposes time saving and cost effective strategies for in vivo target validation and drug development programs. genOway offers cutting-edge technologies (humanization, RNAi, inducible systems) aimed at enhancing the security and relevancy of in vivo projects. genOway has established international relations with major leading pharmaceutical companies and academic research institutes in Europe, North America and Japan. genOway is the only company that combines reliable technology platforms for the development of both mouse and rat models: Rat models: genOway is setting up the first technology platform in the world allowing the development of genetically targeted rat models. In 2003, genOway has published in Science (Zhou et al, 2003) the success in producing the world’s first cloned rats by applying a proprietary technology platform derived from nuclear transfer. These results pave the way for the development of Knock out and Knock in rats. Mouse models: Our technology platform comprises technologies classically used in trangenesis such as Knock-out, Knock-in, Conditional and Inducible systems and several innovative patented approaches such as "Conditional HumanizationTM”, “Safe DNA TransgenesisTM”, “Safe RNAi TransgenesisTM”, “Safe Large DNA TransgenesisTM”, “Safe Knock-outTM”, “Quick Knock-inTM”, “Safe in vivo RNAiTM”.

GRAND TOULOUSE

Economic Development Department 1, Place de la Légion d'Honneur BP 5821
31505 Toulouse - FRANCE

Phone : +33 534 415 940
Fax : +33 534 415 948
Web Site : www.grandtoulouse.org

The Grand Toulouse urban district brings together 25 towns and 600.000 inhabitants. This inter-community dimension means the greater urban district can reinforce its presence at a european and international level. It creates an economic dynamism and fosters shared development projects. Among other missions, Grand Toulouse contributes to the location of major industrial and scientific projects. For instance, Grand Toulouse is setting up the South-West France Canceropole, a joint public and private complex dedicated to the battle against cancer, which will bring together 2.200 researchers on a 220 hectares site. This center will be one of the centres of attraction of European research.


	HELIOS BIOSCIENCES

24 rue du Fb St Jacques
75014 Paris - FRANCE

Phone : +33 153 105 340
Fax : +33 153 105 311
Web Site : www.heliosbiosciences.com

To accurately characterize therapeutic targets HELIOS BIOSCIENCES brings a new paradigm in systems biology by introducing the dynamic dimension in the study of biological regulatory pathways. We build directed networks of intermolecular interactions and develop software to model the dynamics of these network’s responses after pathological / pharmacological stimuli. The company offers access to its molecular interaction networks and the opportunity to co-develop dynamic models of these networks. 1. Algorithmes and Sotwares to Modelize and Predict the evolution of molecular networks during physio-pathological processus. 2. Because no networks of interactions are accurate enough to sustain the development of our dynamic system biology approach, we have developped an outsatnding know-how and expertise in building networks of molecular interactions. 3. Technologies to characterize the expression of genes in tissue sections.


	HTL

Z.I. de L'Aumaillerie
35133 Javené - FRANCE

Phone : +33 299 993 737
Fax : +33 299 990 536
Web Site : www.javenech.com

HTL SARL, created in 1991, is specialized in the manufacture and purification of biotechnological molecules. It's cGMP factory is dedicated to sodium hyaluronate (HA) production by biosynthesis using a natural, non OGM, bacterial strain. HTL has Certificates of Suitability with the European Pharmacopoeia for low and high Mw Sodium Hyaluronate and was Certified ISO 9002 in 1997 and ISO 9001 (2000) in 2003. Further it has a Master File (MAF) filed with both the FDA (US) and the TGA (Australia). HTL is able to tailor make HA to client specification and can produce Mw ranges from 100k Dalton to 3 million Dalton. Production of pharmaceutical Sodium Hyaluronate.


	IPSOGENE SAS

Luminy Biotech Entreprises
163 Avenue de Luminy
Case 923
13288 Marseille - FRANCE

Phone : +33 491 293 090
Fax : +33 491 293 099
Web Site : www.ipsogen.com


	IMAXIO

Biopôle Clermont Limagne
63360 SAINT BEAUZIRE - FRANCE

Phone : +33 473 644 390
Fax : +33 473 644 393
Web Site : www.imaxio.com

Imaxio (formerly Avidis) is an integrated Biotech company with three divisions. aXent uses a proprietary adjuvant-free immunization technology for veterinary and human vaccine applications (www.imaxio.com). Diagnogene provides services based on proprietary and Agilent DNA chips, notably CGH microarray analyses (www.diagnogene.fr). OverExpress sells unique and standard bacterial expression strains (www.overexpress.com). aXent, Imaxio’s Immunization without Adjuvants technology, dramatically improves recombinant antigens’ immunogenicity. Weak antigens, modified for fusion to a small protein domain, trigger a stunning immune response. Various antigens and routes of administration (recombinant proteins, DNA vaccination, viral vectors) have been successfully tested in several species (mice, rabbits and pigs), eliciting faster and higher immune responses. Applications lie in the fields of human and animal vaccination, immunotherapeutics and antibody generation.

INSTITUT
GUSTAVE ROUSSY

39 rue Camille Desmoulins
Pavillon de la recherche II
94805 VILLEJUIF Cedex - FRANCE

Phone : +33 142 114 211
Fax : +33 142 115 300

IGR&D was created by Institute Gustave Roussy. The Institute Gustave Roussy (IGR) is a non-profit private institution, exclusively devoted to Oncology. IGR&D’s mission is primarily to protect and exploit commercial opportunities arising from the research base of IGR, in the fields of Oncology. IGR&D has an early opportunity to assess the commercial potential of the leading-edge research emanating from IGR combined with the flexibility to make commercialisation decisions as these opportunities move through identification, market validation and demonstration and into exploitation.


	ITEC SERVICES

3, Avenue Georges Clémenceau
Z.I Jean Zay
33150 CENON - FRANCE

Phone : +33 557 778 500
Fax : +33 557 778 501

ITEC SERVICES has conducted clinical research for more than 20 years, helping the pharmaceutical industry in clinical trials.It provides comprehensive clinical expertise to meet the needs of its clients.Our services (Pre-Marketing/Post-Marketing) provide clients with drug development solutions and the full range of clinical research facilities. Additional Company Information: 1.Strategic and development advice ITEC SERVICES-In-house experts and specialist consultants are able to assist the pharmaceutical industry with:Global strategies for new product developing, scientific communications, market positioning (Literature searches, Analyses or meta-analyses of clinical trials, Bibliography reports Organising meetings of national and international experts,Regulatory advice,Evaluative reports.Development plans:Clinical study concept (Protocol design,Case report form design),Disease management (Clinical evaluation of hospital care,Medical and economic evaluations of treatment strategies in hospitals and general practice). ...


LYONBIOADVISOR

Aderly, place de la Bourse
69289 Lyon - FRANCE

Phone : +33 472 405 632
Fax : +33 472 405 735
Web Site : www.lyonbioadvisor.com

Lyon BioAdvisor is the first customized service providing a pilot dedicated to ensure the success of your partnership projects. Encompassing 66 000 jobs in life science, Lyon BioAdvisor speeds up your access to expertise, activates its network and mobilizes all the resources you need. Aiming to promote Lyon as one of the top 5 European bio clusters especially in the fields of viro immunology/vaccine and cancer, it has developed an extensive package of supports for inward investments, creation, development of biotech companies, dedicated premises and international events (Biovision, Biosquare).


	MABGENE

Impasse des chênes rouges Quartier du Rieu
30319 ALES Cedex - FRANCE

Phone : +33 466 564 080
Fax : +33 466 564 089
Web Site : www.mabgene.com

MAbgène is an independent French biotechnology company based in Alès, near Montpellier in the south of France. The company was established in december 1997 specifically to develop and manufacture recombinant proteins and monoclonal antibodies by using cell culture techniques on a contract basis for both the private and public sectors. MAbgène offers a comprehensive range of production services using fully documented procedures and state-of-the-art technology in a new facility. The company prides itself in working in close collaboration with its clients to the mutual benefit of both parties. In addition to contrat production from client cell lines, Mabgène has knowledge in the field of expression in different animal cells system. MAbgène is closed to become a pharmaceutical establishment in order to be able to realize the manufactured products for clinical trials.


	MAGNISENSE

BL41 - 112, av. du Général de Gaulle 93118 Rosny-sous-Bois cedex - FRANCE

Phone : +33 148 948 586
Fax : +33 148 940 385
Web Site : www.magnisense.com

Magnisense is a privately held company that develops and markets a new generation of immunoassays for human and animal diagnostics, food safety and environmental protection. These innovative immunoassays are based on magnetic particle markers, which deliver the accuracy of laboratory testing with the ease of use of rapid test methods currently on the market. Magnisense’s technological breakthrough lies in its ability to detect magnetic particles. Magnisense’s MIAtek™ technology allows the detection and precise quantification of a biological target using superparamagnetic particles as markers. These particles are free of interference from environmental factors that may affect other approaches, and replace the currently used enzyme- or fluorescence-based markers. MIAtek™ was developed from research carried out by the Russian Academy of Sciences. Magnisense is developing two application areas: MIAstrip™: Point of care testing with a single sample, producing objective, quantifiable and traceable results via a portable reader for cardiac, tetanus, microbial or viral infection markers among others. MIAflo™: Disposable cartridges for detection of bacterial contamination in food products, e.g. Listeria and Salmonella, or in water, e.g. Legionella, with a sensitivity that brings a significant reduction in testing time.


	MEDICEN

MEDICEN PARIS REGION
6 rue Alexandre Cabanel
75015 Paris - FRANCE

Phone : + 33 144 493 000
Fax : +33 144 493 005

The Medicen Paris Region cluster unites all the key life science and healthcare players in the Paris metropolitan area. Located at the heart of Europe’s leading regional economy, the cluster brings together the highest concentration of healthcare expertise and resources in Europe.
It also leverages the assets to be found in of the world’s leading metropolises including financial infrastructure, real estate and transportation networks.

Medicen Paris Region's success is founded on three strategic pillars:
• global excellence in education and research (including clinical research);
• inter-stakeholder synergy for industrially attractive outputs and
• a globally competitive market for financing life science innovation and entrepreneurial businesses.

Medicen Paris Region's top priority is to boost the region's competitiveness and international attractiveness in terms of high-level therapeutic innovations, generating high added-value jobs in the life sciences.

In order to achieve its objectives, Medicen Paris Region relies on the synergy between the cluster's various stakeholders and notably the major pharmaceutical and healthcare technology companies, biotech & medtech entrepreneurs, public- and private-sector research organizations, hospital networks, universities and other higher education establishments and the region's professional bodies and local authorities.

Medicen Paris Region has also adopted a strategy focusing on six scientific and therapeutic fields in which the region's players are at world-level leadership: nervous system disease, oncology, infectious disease, molecular & cellular therapies, biomedical imaging and drug science & technology.
Interaction between these therapeutic and technological areas of excellence constitutes the very essence of the cluster and is its main driver for innovation.

Medicen Paris Region accredits and supports collaborative R&D projects, thus allowing a large number of companies and institutions to be granted public funding.

In addition, Medicen Paris Region supports the development of several new technology platforms (whether scientific, technological or medical) aimed at facilitating the development of new R&D activities in the Paris Region, at the best world competitive level, consistent with the cluster’s focus areas.


	MIDI PYRÉNÉES EXPANSION

1, place Alfonse Jourdain BP 841
31015 TOULOUSE CEDEX 6 - FRANCE

Phone : +33 561 125 728
Fax : +33 561 125 700
Web Site : www.invest-in-midipyrenees.com

Midi-Pyrenees Expansion is the development Agency of the booming hi-tech region (mainly aeronautics, information technology and biotech) in South-West France, centred around Toulouse. Within La Cité des Biotechnologies®, the Agency partners with Incubators, small business centers (Prologue Biotech, CEEI Theogone), technological platforms and tech-transfer structures, we serve companies and entrepreneurs who develop an activity in our region, such as Actigenics, ADB Pharma, Affichem, BT Pharma, Millegen, Physiogenex, Physiostim

French Bio 2007 Exhibitors